Mechanistic and phase I clinical evaluation of HSP70/miR-22-3p-enriched IFN-γ–MSC-EVs for Th2 signaling suppression in atopic dermatitis

BRE-AD01 - Brexogen

Rinvoq (upadacitinib) - AbbVie

Jimin Kim* 1; Minyoung Jung 1; Seon-Yeong Jeong 1; Jiyeon Lee 1; Insook Cho 2; Seungtaek Oh 2; Zelma Chiesa Fuxench 3; Soo Kim 1,2

May 18, 2026